Activating mutations in PIK3CA, the gene encoding the p110α catalytic domain of PI3K, is one of the frequently altered genes in HR+ breast cancer (~40%) and is implicated in resistance to therapy [11,12,13]. Here, PIK3CG is linked to breast carcinoma.